Challenges documenting racial disparities in Merkel cell carcinoma.
Mackenzie R MartinNoreen MohsinSerena M VilasiDanielle ReedIsaac BrownellPublished in: Cancer biology & therapy (2022)
Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer that predominantly impacts White patients. Overall incidence and the proportion of minority patients with MCC are both rising. In the more common skin cancer, melanoma, racial disparities are well-documented in stage at presentation and patient survival. Whether racial and ethnic disparities exist in MCC remains unclear. The study of MCC disparities is hampered by limitations in data registries, including SEER and NCDB, and an evolving natural history due to the advent of immunotherapy. Published MCC immunotherapy clinical trials consistently reported the racial diversity among enrolled subjects but failed to include patients' ethnicities. Efforts to improve data capture in cancer registries and create multi-institutional clinical databases will allow for more effective study of racial and ethnic disparities in rare cancers like MCC. Such studies are needed to advance policies promoting equity in care.
Keyphrases
- skin cancer
- end stage renal disease
- clinical trial
- african american
- newly diagnosed
- chronic kidney disease
- affordable care act
- prognostic factors
- healthcare
- peritoneal dialysis
- public health
- risk factors
- quality improvement
- squamous cell carcinoma
- case report
- big data
- randomized controlled trial
- young adults
- patient reported outcomes
- pain management
- papillary thyroid
- global health
- free survival
- squamous cell